{'fraction_non_alphanumeric': 0.03319502074688797, 'fraction_numerical': 0.008298755186721992, 'mean_word_length': 5.527027027027027, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Extended mortality results for prostate cancer screening in the PLCO trial with median follow‐up of 15 years

Two large‐scale prostate cancer screening trials using prostate‐specific antigen (PSA) have given conflicting results in terms of the efficacy of such screening. One of those trials, the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, previously reported outcomes with 13 years of follow‐up. This study presents updated findings from the PLCO trial.